1039750-63-4

Basic information

• Product Name: (S,E)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide
• Synonyms: (S,E)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide
• CAS NO: 1039750-63-4
• Molecular Weight: 302.235
• Mol File: 1039750-63-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S,E)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S,E)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide(1039750-63-4)
• EPA Substance Registry System: (S,E)-N-(1-(4-bromophenyl)ethylidene)-2-methylpropane-2-sulfinamide(1039750-63-4)

Safety Data

• Hazardous Substances Data: 1039750-63-4(Hazardous Substances Data)

Upstream product

• 99-90-1 para-bromoacetophenone 
• 343338-28-3 (S)-2-methylpropane-2-sulfinamide 

Downstream Products

• 1438984-03-2 (S)-N-((S)-1-(4-bromophenyl)ethyl)-2-methylpropane-2-sulfinamide 
• 84499-77-4 (S)-α-(p-bromophenyl)ethylamine hydrochloride 
• 1616493-75-4 C₂₁H₂₄BrNO₂S 
• 1616493-99-2 C₂₀H₂₃Br₂NO₂S 
• 1616493-93-6 C₂₁H₂₃Br₂NO₂S 
• 1616493-91-4 C₂₁H₂₃BrClNO₂S 
• 1616493-90-3 C₂₁H₂₃BrFNO₂S 
• 1616493-88-9 C₂₁H₂₃Br₂NO₂S 
• 1616493-86-7 C₂₁H₂₃BrClNO₂S 
• 1616493-84-5 C₂₁H₂₃BrFNO₂S 
• 1616493-83-4 C₂₂H₂₆BrNO₂S 

Relevant articles and documents

Asymmetric Synthesis of Pyrrolidine-Containing Chemical Scaffolds via Tsuji–Trost Allylation of N-tert-Butanesulfinyl Imines

A simple and efficient asymmetric synthesis of novel sp3-rich pyrrolidine chemical scaffolds over five steps starting from simple ketones is described. Key steps involve the use of tert-butanesulfinamide as a chiral auxiliary to perform an asym

N-BIPHENYLMETHYLBENZIMIDAZOLE MODULATORS OF PPARG

The invention provides molecular entities that bind with high affinity to PPARG (PPAR?), inhibit cdk5-mediated phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes or obesity. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.